• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

是一种抗炎共生菌，在代谢性肝病患者的肠道微生物群中丰度降低。

Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease.

机构信息

Université Paris-Saclay, INRAE, MGP, MetaGenoPolis, 78350 Jouy-en-Josas, France.

NovoBiome, 33360 Latresne, France.

出版信息

Int J Mol Sci. 2023 Jul 31;24(15):12232. doi: 10.3390/ijms241512232.

DOI:10.3390/ijms241512232
PMID:37569608
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10418321/
Abstract

Non-alcoholic fatty liver disease (NAFLD) affects about 20-40% of the adult population in high-income countries and is now a leading indication for liver transplantation and can lead to hepatocellular carcinoma. The link between gut microbiota dysbiosis and NAFLD is now clearly established. Through analyses of the gut microbiota with shotgun metagenomics, we observe that compared to healthy controls, is depleted in patients with liver diseases such as NAFLD. Its abundance also decreases as the disease progresses and eventually disappears in the last stages indicating a strong association with disease severity. Moreover, we show that possesses anti-inflammatory properties, both in vitro and in vivo in a humanized mouse model of NAFLD. Therefore, our results demonstrate a link between NAFLD and the severity of liver disease and the presence of and its anti-inflammatory actions. Counterbalancing dysbiosis with this bacterium may be a promising live biotherapeutic strategy for liver diseases.

摘要

非酒精性脂肪性肝病 (NAFLD) 影响高收入国家约 20-40%的成年人群，现已成为肝移植的主要指征，并可导致肝细胞癌。肠道微生物失调与 NAFLD 之间的联系现已明确。通过对肠道微生物组进行鸟枪法宏基因组学分析，我们观察到与健康对照组相比，在患有肝脏疾病（如非酒精性脂肪性肝病）的患者中，该菌的丰度降低。随着疾病的进展，其丰度也会降低，最终在疾病的晚期消失，这表明其与疾病严重程度密切相关。此外，我们还表明，该菌具有抗炎特性，无论是在体外还是在非酒精性脂肪性肝病的人源化小鼠模型中。因此，我们的结果表明，NAFLD 与肝脏疾病的严重程度以及 菌的存在及其抗炎作用之间存在关联。用这种细菌来平衡微生态失调可能是治疗肝脏疾病的一种很有前途的活体生物治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/3608c649374b/ijms-24-12232-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/7626c5757c99/ijms-24-12232-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/6cdc9a153a52/ijms-24-12232-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/370a51a984b5/ijms-24-12232-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/66212ec34cc5/ijms-24-12232-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/f5bd4d125b59/ijms-24-12232-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/89d5f3df894f/ijms-24-12232-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/798e795679d8/ijms-24-12232-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/7a3444d47722/ijms-24-12232-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/e3302eb4395b/ijms-24-12232-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/3608c649374b/ijms-24-12232-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/7626c5757c99/ijms-24-12232-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/6cdc9a153a52/ijms-24-12232-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/370a51a984b5/ijms-24-12232-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/66212ec34cc5/ijms-24-12232-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/f5bd4d125b59/ijms-24-12232-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/89d5f3df894f/ijms-24-12232-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/798e795679d8/ijms-24-12232-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/7a3444d47722/ijms-24-12232-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/e3302eb4395b/ijms-24-12232-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcc9/10418321/3608c649374b/ijms-24-12232-g010.jpg

相似文献

1
Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease.是一种抗炎共生菌，在代谢性肝病患者的肠道微生物群中丰度降低。
Int J Mol Sci. 2023 Jul 31;24(15):12232. doi: 10.3390/ijms241512232.
2
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.了解肠道微生物组和微生物代谢物在非酒精性脂肪性肝病中的作用：当前的证据和观点。
Biomolecules. 2021 Dec 31;12(1):56. doi: 10.3390/biom12010056.
3
Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.回肠胆汁酸转运蛋白抑制剂通过改善非酒精性脂肪性肝病模型小鼠肠道微生物失调改善肝脂肪变性。
mBio. 2021 Aug 31;12(4):e0115521. doi: 10.1128/mBio.01155-21. Epub 2021 Jul 6.
4
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.非酒精性脂肪性肝病的严重程度与肠道菌群失调及肠道微生物群代谢功能的改变有关。
Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13.
5
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.非酒精性脂肪性肝病中的肠道菌群失调：发病机制、诊断和治疗意义。
Front Cell Infect Microbiol. 2022 Nov 8;12:997018. doi: 10.3389/fcimb.2022.997018. eCollection 2022.
6
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.膳食胆固醇通过调节肠道微生物群和代谢物驱动脂肪肝相关肝癌的发生。
Gut. 2021 Apr;70(4):761-774. doi: 10.1136/gutjnl-2019-319664. Epub 2020 Jul 21.
7
Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.肠道微生物群和胆汁酸部分介导了成纤维细胞生长因子21对蛋氨酸-胆碱缺乏饮食诱导的非酒精性脂肪性肝病小鼠的改善作用。
Free Radic Biol Med. 2023 Feb 1;195:199-218. doi: 10.1016/j.freeradbiomed.2022.12.087. Epub 2022 Dec 28.
8
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?益生菌在非酒精性脂肪性肝病中的作用：肠道微生物组是否重要？
Nutrients. 2019 Nov 19;11(11):2837. doi: 10.3390/nu11112837.
9
Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.特定代谢辅因子组合可调节与非酒精性脂肪性肝病相关的微生物失调和肠道屏障功能障碍。
Int J Mol Sci. 2022 Nov 8;23(22):13675. doi: 10.3390/ijms232213675.
10
Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.台湾经活检证实的非酒精性脂肪性肝病患者的肠道微生物失调：一项横断面研究。
Nutrients. 2020 Mar 19;12(3):820. doi: 10.3390/nu12030820.

引用本文的文献

1
Gestational exposure to HIV drugs alters intestinal mucosa-associated microbial diversity in adult rat offspring.孕期接触抗HIV药物会改变成年大鼠后代肠道黏膜相关微生物的多样性。
Exp Biol Med (Maywood). 2025 Aug 13;250:10564. doi: 10.3389/ebm.2025.10564. eCollection 2025.
2
Oral Administration of an Fruit Extract Induces Changes in Gut Microbiota Composition: Relationship with Its Anti-Obesity and Anti-Steatotic Effects in Rats Fed a High-Fat High-Fructose Diet.口服一种水果提取物可诱导肠道微生物群组成的变化：与高脂高果糖饮食喂养大鼠的抗肥胖和抗脂肪变性作用的关系。
Foods. 2025 Aug 20;14(16):2891. doi: 10.3390/foods14162891.
3

本文引用的文献

1
CheckM2: a rapid, scalable and accurate tool for assessing microbial genome quality using machine learning.CheckM2：一种使用机器学习快速、可扩展且准确评估微生物基因组质量的工具。
Nat Methods. 2023 Aug;20(8):1203-1212. doi: 10.1038/s41592-023-01940-w. Epub 2023 Jul 27.
2
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons.全球非酒精性脂肪性肝病发病率：63 项研究和 1,201,807 人的系统评价和荟萃分析。
J Hepatol. 2023 Aug;79(2):287-295. doi: 10.1016/j.jhep.2023.03.040. Epub 2023 Apr 9.
3
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
Association Between Endogenous Equol Production and the Onset of Overactive Bladder in Postmenopausal Women.
绝经后女性内源性雌马酚产生与膀胱过度活动症发病之间的关联。
J Clin Med. 2025 Jun 12;14(12):4183. doi: 10.3390/jcm14124183.
4
Interplay of gut microbiome and metabolome in various blood pressure phenotypes based on ambulatory BP monitoring reveal new insights in nondipper patients.基于动态血压监测的不同血压表型中肠道微生物组与代谢组的相互作用为非勺型患者带来了新见解。
J Hypertens. 2025 Sep 1;43(9):1539-1553. doi: 10.1097/HJH.0000000000004086. Epub 2025 Jun 23.
5
Role of peroxisome proliferator-activated receptor alpha in neurodegenerative diseases and other neurological disorders: Clinical application prospects.过氧化物酶体增殖物激活受体α在神经退行性疾病和其他神经系统疾病中的作用：临床应用前景
Neural Regen Res. 2025 Jun 19. doi: 10.4103/NRR.NRR-D-24-01371.
6
Probiotic-induced enrichment of increases gut microbiome wellness index and maps to lower host blood glucose levels.益生菌诱导的[具体物质]富集可提高肠道微生物群健康指数，并与宿主较低的血糖水平相关。 （注：原文中“increases gut microbiome wellness index and maps to lower host blood glucose levels”部分缺少关键信息，推测是“Probiotic-induced enrichment of [具体物质]”，这里按推测完整意思翻译，具体需根据完整准确原文调整）
Gut Microbes. 2025 Dec;17(1):2520407. doi: 10.1080/19490976.2025.2520407. Epub 2025 Jun 14.
7
Dynamic flexibility of the murine gut microbiota to morphine disturbance enables escape from the stable dysbiosis associated with addiction-like behavior.小鼠肠道微生物群对吗啡干扰的动态灵活性能够避免与成瘾样行为相关的稳定失调。
bioRxiv. 2025 Jun 1:2025.06.01.657215. doi: 10.1101/2025.06.01.657215.
8
Multi-strain probiotics attenuate carbohydrate-lipid metabolic dysregulation in type 2 diabetic rats via gut-liver axis modulation.多菌株益生菌通过调节肠-肝轴减轻2型糖尿病大鼠的碳水化合物-脂质代谢失调。
mSystems. 2025 Jul 22;10(7):e0036925. doi: 10.1128/msystems.00369-25. Epub 2025 Jun 10.
9
Gallic acid prevents obesity in mice on a high-fat diet via the gut microbiota-adipose tissue axis.没食子酸通过肠道微生物群 - 脂肪组织轴预防高脂饮食小鼠肥胖。
Curr Res Food Sci. 2025 May 16;10:101084. doi: 10.1016/j.crfs.2025.101084. eCollection 2025.
10
From Diet to Scar: Novel Mendelian Randomization and Mediation Analyses Linking Dietary Habits, Gut Microbiota, and Hypertrophic Scarring.从饮食到瘢痕：新型孟德尔随机化和中介分析揭示饮食习惯、肠道微生物群与肥厚性瘢痕之间的联系
Food Sci Nutr. 2025 May 28;13(6):e70292. doi: 10.1002/fsn3.70292. eCollection 2025 Jun.
非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的全球流行病学：系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
4
Microbiome-derived ethanol in nonalcoholic fatty liver disease.微生物组衍生的乙醇在非酒精性脂肪性肝病中的作用。
Nat Med. 2022 Oct;28(10):2100-2106. doi: 10.1038/s41591-022-02016-6. Epub 2022 Oct 10.
5
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms.黏蛋白阿克曼氏菌：新一代有益微生物的范例。
Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):625-637. doi: 10.1038/s41575-022-00631-9. Epub 2022 May 31.
6
Breakthroughs in therapies for NASH and remaining challenges.NASH 治疗方面的突破和尚存的挑战。
J Hepatol. 2022 Jun;76(6):1263-1278. doi: 10.1016/j.jhep.2022.04.002.
7
sp. nov., an equol non-producing bacterium isolated from human faeces.一株新的、从人粪便中分离得到的不能产生雌马酚的细菌。
Int J Syst Evol Microbiol. 2021 Dec;71(12). doi: 10.1099/ijsem.0.005121.
8
Dynamic Properties of the Intestinal Ecosystem Call for Combination Therapies, Targeting Inflammation and Microbiota, in Ulcerative Colitis.肠道生态系统的动态特性要求针对炎症和微生物群采用联合疗法治疗溃疡性结肠炎。
Gastroenterology. 2021 Dec;161(6):1969-1981.e12. doi: 10.1053/j.gastro.2021.08.057. Epub 2021 Sep 8.
9
sp. nov., a resveratrol-metabolizing bacterium isolated from human faeces and emended description of the genus .一株新的白藜芦醇代谢菌，从人粪便中分离出来，并对属的描述进行了修正。
Int J Syst Evol Microbiol. 2021 Sep;71(9). doi: 10.1099/ijsem.0.004987.
10
Human reference gut microbiome catalog including newly assembled genomes from under-represented Asian metagenomes.人类参考肠道微生物组目录，包括来自代表性不足的亚洲宏基因组的新组装基因组。
Genome Med. 2021 Aug 27;13(1):134. doi: 10.1186/s13073-021-00950-7.